SENSITIVITY AND SPECIFY OF GENOTYPING METHODS IN DIAGNOSIS OF MULTI- AND EXTENDED-DRUG RESISTANT TUBERCULOSIS AND NON-TUBERCULOSIS MYCOBACTERIAL DISEASES
Abstract
In review, the test-systems GenoType® practical importance in diagnosis of multi- and extended-drug resistant TB and nontuberculosis mycobacterial diseases is considered. Plenty of studies confirmed the high diagnostic specificity and sensitivity of GenoType® MTBDRplus in isoniazid and rifampin drug resistance detection. From 2009 г. this test is recommended for TB detection by WHO. The high rates of diagnostic specificity and sensitivity of GenoType® MTBDRsl in ofloxacin drug resistance were also obtained, but, due to the insufficient specificity and sensitivity in detection of resistance to injectable TB drugs and ethambutol, this test isn’t recommended for XDR-TB detection by WHO. The GenoType® Mycobacterium CM/ AS implementation provide for non-tuberculosis mycobacteria
detection with high-level diagnostic specificity and sensitivity. The GenoType® test-systems can be used in routine practice of TB facilities for diagnosis of multi- and extended-drug resistant TB and nontuberculosis mycobacterial diseases.
About the Authors
O. A. Maryandyshev
ГБОУ ВПО «Северный государственный медицинский университет» Минздрава России
Russian Federation
Russian Federation
P. I. Eliseev
ГБУЗ Архангельской области «Архангельский клинический противотуберкулезный диспансер»
Russian Federation
Russian Federation
References
1. Елисеев П.И., Никишова Е.И., Горина Г.П., Марьяндышев А.О. Результаты применения методов GenoType MTBDRplus и BACTEC MGIT для определения лекарственной чувствительности возбудителя туберкулеза // Туберкулез и болезни легких. − 2012. – № 6. – С. 31-34.
2. Елисеев П.И., Тарасова И.В., Никишова Е.И., Марьяндышев А.О. Результаты применения метода GenoType MTBDRsl для определения лекарственной чувствительности возбудителя туберкулеза к этамбутолу, офлоксацину, канамицину и капреомицину в Архангельской области // Туберкулез и болезни легких. – 2013. – № 1. – С. 32-36.
3. Николаевский В.В., Балабанова Я.М., Миронова С.А. и др. Чувствительность и специфичность молекулярно-генетической тест-системы HAIN MTBDRplus для экспресс-диагностики лекарственной чувствительности микобактерий туберкулеза на материале мокроты // Туберкулез и болезни легких. – 2010. – № 4. – C. 28-34.
4. Макарова М.В. Нетуберкулезные микобактерии: Классификация, эпидемиология, патология у людей и животных, лабораторная диагностика (обзор литературы) // Туберкулез и болезни легких. – 2007. – № 10. – С. 7-17.
5. Туберкулез в Российской федерации 2010 г. Аналитический обзор статистических показателей, используемых в Российской Федерации. – М., 2011. – 280 с.
6. Anek-vorapong R., Sinthuwattanawibool C., Podewils L. et al. Validation of the GenoType® MTBDRplus assay for detection of MDR-TB in a public health laboratory in Thailand // BMC Inf. Dis. – 2010. – Vol. 10. – Article 123. – doi: 10.1186/1471-2334-10-1233.
7. Brossier F., Veziris N., Aubry F. et al. Detection by Genotype MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates // J. Clin. Microbiol. – 2010. – Vol. 48. – P. 1683-1689.
8. Bwanga F., Hoffner S., Haile M., Joloba M. Direct susceptibility testing for multidrug resistant tuberculosis: A meta-analysis // BMC Infect. Dis. – 2009. – Vol. 9. – Article 67. – doi:10.1186/1471-2334-9-67.
9. Cavusoglu C., Turhan A., Akinci P., Soyler I. Evaluation of the Genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis isolates // J. Clin. Microbiol. – 2006. – Vol. 44. – N. 7. – P. 2338-2342.
10. Campbell P., Morlock G., Sikes R. et al. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis // Antimicrob. Agents Chemother. – 2011. –Vol. 55. – N. 5. – P. 2032-2041.
11. Chryssanthou E., Angeby K. The GenoType® MTBDRplus assay for detection of drug resistance in Mycobacterium tuberculosis in Sweden // APMIS. – 2012. – Vol. 120. – N. 5 – P. 405-409.
12. Global tuberculosis report 2010. – World Health Organization, Geneva, 2010.
13. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO 2011 update. – World Health Organization, Geneva, 2006.
14. Hillemann D., Rusch-Gerdes S., Richter E. Feasibility of the Genotype MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens // J. Clin. Microbiol. – 2009. – Vol. 47. – N. 6 – P. 1767-1772.
15. Huang W., Chi T., Wu M., Jou R. Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis // J. Clin. Microbiol. – 2011 – Vol. 49. – N. 7. – P. 2502-2508.
16. Huyen M., Tiemersma E., Lan N. Et al. Validation of the GenoType® MTBDRplus assay for diagnosis of multidrug resistant tuberculosis in South Vietnam // BMC Infect. Dis. – 2010. – Vol. 10. – Article 149. – doi: 10.1186/1471-2334-10-1499.
17. Ingen J., Simons S., Zwaan R. Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates // J. Clin. Microbiol. – 2010. – Vol. 48. – P. 2749-2753.
18. Instructions for use – Genotype MTBDRsl, Ver. 1.0. – Hain Lifescience, 2009.
19. Lee A.S., Jelfs P., Sintchenko V., Gilbert G. Identification of non-tuberculous mycobacteria: utility of the GenoType Mycobacterium CM/AS assay compared with HPLC and 16S rRNA genesequencing // J. Medical Microb. – 2009. – P. 900 –904.
20. Ling D.I., Zwerling A., Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis // ERJ. – 2008. – Vol. 32. – N. 5. – P. 1165-1174.
21. Mironova S., Pimkina E., Kontsevaya I. Performance of the GenoType® MTBDRPlus assay in routine settings: a multicenter study // Eur. J. Clin. Microb. Infect. Dis. – 2012 – Vol. 31. – N. 7. – P. 1381-1387.
22. Nikolayevskyy V., Balabanova Y., Simak T. Performance of the Genotype® MTBDRPlus assay in the diagnosis of tuberculosis and drug resistance in Samara, Russian Federation // BMC Clin. Pathol. – 2009. – Vol. 9. – Article 2. – doi:10.1186/1472-6890-9-2.
23. O’Donnell N., Corcoran D., Lucey B., Barrett A. Molecular-based mycobacterial identification in a clinical laboratory setting: a comparison of two methods // Brit. J. Biomed. Science. – 2012. – Vol. 69. – N. 4. – P. 164-168.
24. Phillips L. TB’s revenge // Nature. – 2013 – Vol. 493. – N. 3. – P. 14-16.
25. Richter E., Rusch-Gerdes S., Hillemann D. Evaluation of the GenoType Mycobacterium assay for identification of Mycobacterial species from cultures // J. Clin. Microbiol. – 2006. – Vol. 44. – N. 5. – P. 1769-1775.
26. Said H., Kock M., Ismail N. et al. Evaluation of the GenoType® MTBDRsl assay for susceptibility testing of second-line anti-tuberculosis drugs // Int. J. Tub. Lung Dis. – 2012 – Vol. 16. − N. 1. – P. 104 – 109.
27. Safianowska A., Walkiewicz R., Nejman-Gryz P. The comparison between two methods for typing of nontuberculous mycobacteria: high pressure liquid chromatography and molecular assay Genotype Mycobacterium CM/AS // Pneumonol. Alergol. Polska. – 2010. – Vol. 78. − N. 5. – P. 363–368.
28. Somoskovi A., Dormandy J., Mitsani D. Use of smear-positive samples to assess the PCR-based Genotype MTBDR assay for rapid, direct detection of the Mycobacterium tuberculosis complex as well as its resistance to isoniazid and rifampin // J. Clin. Microb. – 2006. – Vol. 44. – N. 12. – P. 4459–4463.
29. WHO policy statement – the use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs. – World Health Organization, Geneva., 2013.
Review
For citations:
Maryandyshev O.A., Eliseev P.I. SENSITIVITY AND SPECIFY OF GENOTYPING METHODS IN DIAGNOSIS OF MULTI- AND EXTENDED-DRUG RESISTANT TUBERCULOSIS AND NON-TUBERCULOSIS MYCOBACTERIAL DISEASES. Tuberculosis and socially significant diseases. 2014;(1-2):64-70. (In Russ.)
Views:
24
Email this article 